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iabetes and cardiovascular diseases
arecloselyconnectedﬁeldsofmed-
icine. Diabetes is a major risk factor
and cause of cardiovascular disease and
many patients with cardiovascular disor-
ders, not the least coronary heart disease,
have glucometabolic perturbations (1).
Diabeticpatientswithoutapreviousmyo-
cardial infarction have a risk for cardiac
mortality of 20% over 7 years, which is
largely equal to the risk of nondiabetic
patients after myocardial infarction (3).
Furthermore, the risk for cardiovascular
mortality in diabetic patients with acute
myocardial infarction over a time period
of 7 years has been observed to be up to
45% (3).
In diabetic patients with acute myo-
cardial infarction, hospital mortality has
also been reported to be substantially en-
hanced (4). A twofold increase in total
hospital mortality has been reported in
these patients (5). In 1999, the Munich
Myocardial Infarction Registry reported a
nearly threefold increase in hospital mor-
tality within 24 h after admission (6). A
total of 14% of diabetic patients with
acute myocardial infarction died within
the ﬁrst 24 h compared with 5% in non-
diabetic patients (6). The Munich Myo-
cardial Infarction Registry focuses on the
inpatient management of acute myocar-
dial infarction.
UNDERUSE OF HOSPITAL-
BASED TREATMENT
STRATEGIES— Although mortality-
reducing effects of evidence-based treat-
ment like reperfusion are equally
beneﬁcialinpatientswithandwithoutdi-
abetes, evidence-based treatment has for-
merly somehow been demonstrated to be
less used in diabetic patients (4,6,7). The
initial analysis of the Munich Myocardial
Infarction Registry conﬁrmed the under-
use of early treatment strategies in dia-
betic patients (6). Coronary angiography,
percutaneous transluminal balloon coro-
nary angioplasty, and stenting were per-
formedlessfrequentlyindiabeticpatients
than in nondiabetic patients (6). The un-
derusehadalsobeenreportedinprevious
registries: the Swedish registry (Register
of Information and Knowledge about
Swedish Heart Intensive Care Admission
[RIKS-HIA]) included patients with myo-
cardial infarction, who were admitted be-
tween 1995 and 1998 (7). The Augsburg
MONICAregistry,whichinvestigatedpa-
tients from 1985 to 1992, also observed
underuseoftreatmentstrategies(4).Ithas
been hypothesized, that the resistance to
use advanced treatment options partially
contributes to the poorer outcome in di-
abetic patients compared with nondia-
betic patients (4,7).
STRATEGIES FOR
HOSPITAL-BASED CARE:
INTERDISCIPLINARY
COLLABORATION— In view of
the frequently reported poorer hospital
outcome together with a reduced inten-
sity of early treatment, clinical structures
need to aim at overcoming the unfavor-
able constellation in diabetic patients.
The initiation of a joint task force of
diabetologists, internists, and cardiolo-
gists is the key element to achieve an im-
provement in diabetes care for
hospitalized patients. For the outpatient
care of the patients, a close cooperation
with primary care physicians also needs
to be envisaged.
In the Munich Myocardial Infarc-
tion Registry, the cooperation focuses
both on the treatment of hyperglycemia
and the optimization of early treatment
strategies targeting coronary occlusion
(8). The recent European Society of
Cardiology(ESC)andEuropeanAssoci-
ation for the Study of Diabetes (EASD)
joint guidelines on diabetes, pre-
diabetes, and cardiovascular diseases
emphasize the need for a cooperation
and give practical advice on how to
achievetheearliestdiagnosisofbothdi-
abetes and cardiovascular disease to-
gether with optimized treatment
approaches (9,10).
INTENSIFICATION OF
TREATMENT STRATEGIES
AND REDUCTION OF
MORTALITY— In the Munich Myo-
cardial Infarction Registry, therapeutic
approaches were intensiﬁed as a result of
the activities of the joint task force of dia-
betologists, internists, and cardiologists
(Fig. 1) (8). Initially, coronary angiogra-
phy, transluminal balloon coronary an-
gioplasty, and stenting were performed
less frequently in diabetic patients than in
nondiabeticpatients.Becauseoftheactiv-
ities of the task force, the performance of
these therapeutic options were substan-
tially increased to levels comparable with
those of nondiabetic patients (Fig. 1) (8).
In addition, GbIIb/IIIa receptor agonists
were administered more frequently and
glucose-insulin was initiated to improve
metabolic control (8).
The intensiﬁcation of treatment ap-
proaches translated into a signiﬁcant re-
duction of early hospital mortality in
diabetic patients within 2 years (Fig. 2)
(8). In diabetic patients, total hospital
mortality decreased by 44% and 24-h mor-
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among nondiabetic subjects, however, did
not change signiﬁcantly (Fig. 2) (8).
The increase in the number of thera-
peutic approaches in diabetic patients
with acute myocardial infarction (also
whenadjustedforage,sex,andotherclin-
ical variables) is associated with a reduc-
tion in mortality (8).
EARLY DIAGNOSIS AND
INTENSIVE TREATMENT — There
is evidence that early hospital mortality can
be reduced by a combination of multiple
approaches both targeting vessel occlusion
andhyperglycemia(8).Itseemsthatinsulin
therapy in the acute setting is essential and
contributes to the success (18). The NICE-
SUGARstudyemphasizestheneedtoavoid
hypoglycemic episodes during acute treat-
mentintheintensivecareunit.Inthestudy,
intensive glucose control was associated
with a higher mortality (27.5%) compared
with a conventional glucose control
(24.9%). Severe hypoglycemia was 13-
fold higher in the intensive glucose control
groupthanintheconventionalglucosecon-
trol group (0.5 vs. 6.8%) (16). This may
Figure 1—The Munich Myocardial Infarction Registry: Intensiﬁcation of treatment approaches in 2001 versus 1999 (8). D, diabetes; ND, no
diabetes.
Figure2—TheMunichMyocardialInfarctionRegistry:Reductionofhospitalmortalityinpatientswithacutemyocardialinfarction(8).D,diabetes;
ND, no diabetes.
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mortality.
Theseaspectsarealsoincorporatedin
theESCandEASDguidelinesondiabetes,
pre-diabetes, and cardiovascular disease,
which recommend both earliest diagnos-
tic procedures and therapeutic ap-
proaches (Fig. 3) (9,10).
SILENT DIABETES— It is clear to-
daythatglucosemetabolismisalteredina
large proportion of patients with acute
myocardialinfarctionandnopreviousdi-
agnosisofdiabetes(16).Inthesepatients,
35 and 40% of patients present with im-
paired glucose tolerance at discharge and
after 3 months, respectively, and 31 and
25%haveundiagnoseddiabetes(16).The
high prevalence of impaired glucose tol-
erance and diabetes has been conﬁrmed
by the Euro Heart Survey (13).
ThejointguidelinesoftheESCandEASD
on diabetes, pre-diabetes, and cardiovascular
disease therefore recommend performing an
oral glucose tolerance test in all patients with
coronary artery disease and no previous diag-
nosis of diabetes (Fig. 3) (9,10).
THE MUNICH MYOCARDIAL
INFARCTION REGISTRY:
CURRENT AND FUTURE
DIRECTION— A key element of the
Myocardial Infarction Registry is that it
enables the visualization of the quality of
careofdiabeticpatientsandshowspoten-
tial for an optimization (6,8,11). A regis-
try certainly requires team building and
the readiness to change structures and
initiate clinical pathways (Table 1).
We need to be aware that it is not a
singleapproachmakingallthedifferencein
diabetic patients with acute myocardial in-
farction. It is the use of multiple advanced
treatmentstrategiesthatenableasubstantial
reduction of hospital mortality in patients.
Interventions targeting both arterial occlu-
sion and metabolic disturbances need to be
applied with comparable emphasis (Table
1). Resistance to early diagnostic and thera-
peutic interventions in diabetic patients
needstobefurtherreducedintheadvanced
treatment of a diabetic patient.
Intensiﬁcation of multiple advanced
therapeutic strategies in diabetic patients
with acute myocardial infarction enables a
reductioninhospitalmortalitytoalevelthat
is comparable to those of nondiabetic pa-
tients.Weshouldapplyourcurrentknowl-
edge and evidence to achieve this favorable
situation for every diabetic patient with
acute myocardial infarction (Table 1).
In light of the recent ﬁndings in
ACCORD/VADT/ADVANCE (17–19), it
needs to be emphasized that prevention
ofhypoglycemiamayalsoberegardedasa
key element of a successful approach in
the hospital. The practical implications of
these recent study results for today’s
blood glucose–lowering therapy are not
only the need to avoid side effects such as
hypoglycemia but also the need to pre-
vent weight gain (17–19).
THE ESC AND EASD
GUIDELINES ON DIABETES,
PRE-DIABETES, AND
CARDIOVASCULAR
DISEASE: AN OVERVIEW — The
emergence of new interdisciplinary guid-
Table 1—Munich Myocardial Infarction Registry: Key lessons and recommendations
● Underuse of early treatment approaches in diabetic patients with acute myocardial
infarction is not justiﬁed.
● Intensiﬁcation of early treatment strategies leads to an improvement of hospital
outcome in diabetic patients with acute myocardial infarction.
● Earliest diagnosis of diabetes and pre-diabetes with patients with acute myocardial
infarction and no previous diagnosis of diabetes is essential.
● Registry enables the visualization of the quality of care and opens potentials of an
improvement of the management of the patients.
● Joint task forces of diabetologists and cardiologists are strongly recommended.
From Refs. 6, 8, and 11.
Figure3—InvestigationalalgorithmoftheESC/EASDguidelines(9,10).ACS,acutecoronarysyndrome;ECG,electrocardiogram;MI,myocardial
infarction.
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EASD and the ESC is therefore an impor-
tant and noteworthy step in the develop-
mentof“joined-upthinking”inthisarena
ofmedicine.Theguidelinesfocusonboth
inpatient and outpatient management of
diabetes and cardiovascular disease.
The full-text versions were published
inthejournalDiabetes,Metabolismandthe
Heart for the area of diabetology and in
the European Heart Journal for the area of
cardiology (9,10).
These guidelines are unique in the
sense that they represent the opinion of
leading specialists appointed jointly by
two major professional organizations. In
addition to the medical professions, the
implementationmeetingwelcomedphar-
maceutical industrial representation, in
recognition of the contributions of indus-
try to postgraduate medical education.
A large part of the guidelines is de-
voted to the proper management of pa-
tients with diabetes and various
cardiovascular disease manifestations.
The need for lifestyle and dietary advice
and strict treatment targets for blood glu-
cose, A1C, blood pressure, and blood lip-
ids were reviewed. The care of diabetic
patients with acute coronary syndromes
and those in need for revascularization is
discussed, and some aspects of health
economy and diabetes are summarized.
The need for further improvement of
routine practice in these respects was
highlighted by a consideration of data
from the recent European Heart Survey
on Diabetes and the Heart. From this sur-
vey,itisclearthatriskfactormanagement
and glucose control among European pa-
tients with diabetes and cardiovascular
disease are frequently below the stan-
dards advocated in the guidelines.
As already remarked, diabetes and
pre-diabetes are painless and remain un-
detected if not investigated. Screening for
elevated glucose (pre-diabetes) is there-
fore important for prognostic reasons.
Proposed screening methods, as outlined
in the guidelines, vary. At a population
level, simple web-based questionnaires
may inform people on their actual risk
and motivate those who need to improve
their lifestyle to take steps that may avoid
future development of the disease. Indi-
vidualsataparticularhighrisk(forexam-
ple, those with a strong family history,
established cardiovascular disease, adi-
posity, or previous gestational diabetes)
should be screened with oral glucose tol-
erancetestsatdeﬁnedintervals.(Postload
values are more predictive than fasting
values.)
If a pre-diabetic state is detected, a
modest weight reduction (of the order of
10%), combined with a more physically
active lifestyle, may prevent or retard the
development of overt diabetes. Drugs
such as metformin or acarbose may be
used if lifestyle advice fails.
Table2summarizesthecontentofthe
pocketversionofthesenewguidelineson
diabetes, pre-diabetes, and cardiovascu-
lar diseases and lists the top 10 recom-
mendations of this interdisciplinary
approach to improve the outcome of the
high-risk patients with both diabetes and
cardiovascular diseases (20).
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